Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch-Reference-Cited by-同舟云学术

Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch

Published:2021-10-08 Issue:19 Volume:6 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Tierney J. William^ORCID,Evans Brian C.,Cheung-Flynn Joyce^ORCID,Wang Bo,Colazo Juan M.^ORCID,Polcz Monica E.^ORCID,Cook Rebecca S.,Brophy Colleen M.,Duvall Craig L.^ORCID

Funder

National Institute of Health

National Science Foundation

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/142339/files/pdf

Reference62 articles.

1. The Intima

2. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia.

3. The biology of saphenous vein graft occlusion

4. Taxol (paclitaxel): mechanisms of action;Horwitz;Ann Oncol,1994

5. Sirolimus: its discovery, biological properties, and mechanism of action;Sehgal;Transplant Proc,2003

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravascular delivery of an MK2 inhibitory peptide to prevent restenosis after angioplasty;Biomaterials;2025-02

2. CircLMBR1 inhibits phenotypic transformation of hypoxia-induced pulmonary artery smooth muscle via the splicing factor PUF60;European Journal of Pharmacology;2024-10

3. LncRNA MFRL regulates the phenotypic switch of vascular smooth muscle cells to attenuate arterial remodeling by encoding a novel micropeptide MFRLP;Translational Research;2024-10

4. Hormonal influence: unraveling the impact of sex hormones on vascular smooth muscle cells;Biological Research;2024-09-04

5. Vascular remodelling in cardiovascular diseases: hypertension, oxidation, and inflammation;Clinical Science;2024-06-26